 Craig Della Valle
Concepts (618)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 172 | 2021 | 646 | 36.880 |
Why?
| | Arthroplasty, Replacement, Hip | 176 | 2021 | 819 | 36.700 |
Why?
| | Prosthesis-Related Infections | 85 | 2021 | 204 | 23.550 |
Why?
| | Hip Prosthesis | 85 | 2021 | 554 | 18.110 |
Why?
| | Reoperation | 114 | 2021 | 911 | 12.850 |
Why?
| | Knee Prosthesis | 53 | 2021 | 233 | 12.270 |
Why?
| | Prosthesis Failure | 60 | 2021 | 520 | 8.610 |
Why?
| | Postoperative Complications | 47 | 2021 | 1059 | 6.810 |
Why?
| | Humans | 324 | 2021 | 29841 | 6.790 |
Why?
| | Arthritis, Infectious | 21 | 2021 | 50 | 6.400 |
Why?
| | Aged | 165 | 2021 | 9833 | 6.050 |
Why?
| | Knee Joint | 48 | 2021 | 721 | 5.850 |
Why?
| | Osteoarthritis, Knee | 23 | 2021 | 355 | 5.800 |
Why?
| | Tranexamic Acid | 10 | 2021 | 20 | 5.780 |
Why?
| | Middle Aged | 175 | 2021 | 11053 | 5.730 |
Why?
| | Pain, Postoperative | 21 | 2021 | 293 | 5.680 |
Why?
| | Surgical Wound Infection | 13 | 2019 | 102 | 5.450 |
Why?
| | Synovial Fluid | 25 | 2020 | 137 | 5.430 |
Why?
| | Retrospective Studies | 95 | 2021 | 3303 | 5.290 |
Why?
| | Female | 195 | 2021 | 17657 | 5.270 |
Why?
| | Hip Joint | 23 | 2020 | 323 | 5.040 |
Why?
| | Male | 183 | 2021 | 17153 | 4.990 |
Why?
| | Prosthesis Design | 51 | 2021 | 499 | 4.940 |
Why?
| | Antifibrinolytic Agents | 9 | 2020 | 21 | 4.830 |
Why?
| | Analgesics, Opioid | 10 | 2021 | 182 | 4.490 |
Why?
| | Aged, 80 and over | 95 | 2019 | 5016 | 4.470 |
Why?
| | Anti-Bacterial Agents | 24 | 2021 | 401 | 4.210 |
Why?
| | Hip Dislocation | 11 | 2020 | 57 | 4.060 |
Why?
| | Treatment Outcome | 88 | 2021 | 3788 | 4.020 |
Why?
| | Arthroplasty, Replacement | 11 | 2020 | 143 | 3.920 |
Why?
| | Adult | 113 | 2021 | 9591 | 3.880 |
Why?
| | Pneumonia | 7 | 2019 | 75 | 3.700 |
Why?
| | Acetabulum | 17 | 2020 | 190 | 3.670 |
Why?
| | Femoral Fractures | 11 | 2020 | 42 | 3.340 |
Why?
| | Hip Fractures | 9 | 2018 | 30 | 3.330 |
Why?
| | Risk Factors | 49 | 2021 | 2549 | 3.330 |
Why?
| | Orthopedics | 8 | 2019 | 128 | 3.260 |
Why?
| | Inpatients | 9 | 2019 | 132 | 3.240 |
Why?
| | United States | 43 | 2021 | 2402 | 3.230 |
Why?
| | Outpatients | 8 | 2021 | 48 | 3.090 |
Why?
| | Osteoarthritis, Hip | 13 | 2020 | 95 | 2.980 |
Why?
| | Periprosthetic Fractures | 8 | 2020 | 29 | 2.960 |
Why?
| | Medicare | 15 | 2021 | 99 | 2.920 |
Why?
| | C-Reactive Protein | 19 | 2019 | 132 | 2.910 |
Why?
| | Sepsis | 8 | 2018 | 153 | 2.810 |
Why?
| | Joint Instability | 13 | 2018 | 356 | 2.730 |
Why?
| | Patient Readmission | 13 | 2021 | 111 | 2.720 |
Why?
| | Radiography | 38 | 2020 | 714 | 2.590 |
Why?
| | Blood Loss, Surgical | 9 | 2020 | 71 | 2.550 |
Why?
| | Surgeons | 8 | 2021 | 70 | 2.450 |
Why?
| | Malnutrition | 4 | 2015 | 20 | 2.430 |
Why?
| | Operative Time | 8 | 2021 | 94 | 2.370 |
Why?
| | Urinary Tract Infections | 4 | 2019 | 32 | 2.340 |
Why?
| | Length of Stay | 13 | 2021 | 360 | 2.300 |
Why?
| | Patient Satisfaction | 11 | 2019 | 298 | 2.120 |
Why?
| | Osteotomy | 10 | 2020 | 153 | 2.110 |
Why?
| | Femur | 18 | 2020 | 379 | 2.100 |
Why?
| | Joint Diseases | 7 | 2017 | 114 | 2.070 |
Why?
| | Metals | 14 | 2019 | 154 | 2.070 |
Why?
| | Blood Sedimentation | 17 | 2019 | 65 | 2.020 |
Why?
| | Polyethylene | 10 | 2021 | 126 | 1.960 |
Why?
| | Range of Motion, Articular | 20 | 2020 | 695 | 1.960 |
Why?
| | Metal-on-Metal Joint Prostheses | 7 | 2021 | 52 | 1.870 |
Why?
| | Tibia | 11 | 2021 | 259 | 1.830 |
Why?
| | Prospective Studies | 32 | 2021 | 1809 | 1.820 |
Why?
| | Patient Discharge | 8 | 2021 | 154 | 1.750 |
Why?
| | Pulmonary Embolism | 5 | 2019 | 55 | 1.730 |
Why?
| | Young Adult | 23 | 2020 | 2198 | 1.720 |
Why?
| | Arthroplasty | 7 | 2020 | 124 | 1.700 |
Why?
| | Time Factors | 32 | 2020 | 1894 | 1.700 |
Why?
| | Follow-Up Studies | 34 | 2021 | 2017 | 1.680 |
Why?
| | Bone Cements | 12 | 2017 | 90 | 1.640 |
Why?
| | Debridement | 11 | 2020 | 100 | 1.590 |
Why?
| | alpha-Defensins | 2 | 2018 | 3 | 1.550 |
Why?
| | Risk Assessment | 16 | 2021 | 794 | 1.550 |
Why?
| | Postoperative Hemorrhage | 3 | 2019 | 30 | 1.550 |
Why?
| | Physical Therapy Modalities | 3 | 2019 | 71 | 1.520 |
Why?
| | Hospital Costs | 3 | 2017 | 74 | 1.520 |
Why?
| | Pain Management | 8 | 2020 | 135 | 1.500 |
Why?
| | Quality Improvement | 12 | 2018 | 169 | 1.500 |
Why?
| | Multivariate Analysis | 9 | 2019 | 390 | 1.490 |
Why?
| | Recovery of Function | 19 | 2017 | 301 | 1.480 |
Why?
| | Therapeutic Irrigation | 10 | 2020 | 63 | 1.460 |
Why?
| | Analgesia, Epidural | 2 | 2018 | 63 | 1.460 |
Why?
| | Intraoperative Care | 5 | 2021 | 58 | 1.450 |
Why?
| | Coated Materials, Biocompatible | 7 | 2015 | 42 | 1.420 |
Why?
| | Ownership | 2 | 2017 | 5 | 1.410 |
Why?
| | Patient Education as Topic | 2 | 2020 | 191 | 1.410 |
Why?
| | Intraoperative Complications | 4 | 2016 | 75 | 1.400 |
Why?
| | Serum Albumin | 2 | 2017 | 28 | 1.390 |
Why?
| | Thromboembolism | 4 | 2018 | 38 | 1.390 |
Why?
| | Adolescent | 20 | 2020 | 2591 | 1.390 |
Why?
| | Leukocyte Count | 13 | 2020 | 97 | 1.370 |
Why?
| | Venous Thrombosis | 5 | 2019 | 47 | 1.360 |
Why?
| | Femur Head | 4 | 2015 | 57 | 1.340 |
Why?
| | Ambulatory Surgical Procedures | 6 | 2021 | 79 | 1.330 |
Why?
| | Comorbidity | 11 | 2018 | 555 | 1.310 |
Why?
| | Foreign-Body Reaction | 2 | 2016 | 31 | 1.300 |
Why?
| | Orthopedic Procedures | 7 | 2019 | 316 | 1.300 |
Why?
| | Ambulatory Care | 2 | 2021 | 86 | 1.300 |
Why?
| | Registries | 8 | 2018 | 195 | 1.270 |
Why?
| | Hemiarthroplasty | 2 | 2017 | 29 | 1.270 |
Why?
| | Blood Transfusion | 5 | 2020 | 68 | 1.260 |
Why?
| | Chromium | 6 | 2018 | 95 | 1.250 |
Why?
| | Postoperative Period | 11 | 2020 | 291 | 1.240 |
Why?
| | Cobalt | 6 | 2018 | 106 | 1.240 |
Why?
| | Health Care Costs | 3 | 2021 | 79 | 1.230 |
Why?
| | Sensitivity and Specificity | 16 | 2019 | 592 | 1.230 |
Why?
| | Incidence | 15 | 2018 | 813 | 1.210 |
Why?
| | Analgesia | 4 | 2019 | 39 | 1.190 |
Why?
| | Societies, Medical | 5 | 2021 | 202 | 1.180 |
Why?
| | Prostheses and Implants | 5 | 2017 | 168 | 1.180 |
Why?
| | Body Mass Index | 11 | 2020 | 435 | 1.180 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 382 | 1.160 |
Why?
| | Vancomycin | 4 | 2019 | 53 | 1.160 |
Why?
| | Braces | 2 | 2016 | 26 | 1.160 |
Why?
| | Osseointegration | 6 | 2016 | 69 | 1.130 |
Why?
| | Surgery, Computer-Assisted | 2 | 2019 | 61 | 1.120 |
Why?
| | Prescriptions | 2 | 2021 | 18 | 1.110 |
Why?
| | Odds Ratio | 8 | 2019 | 328 | 1.100 |
Why?
| | Cohort Studies | 14 | 2021 | 1911 | 1.090 |
Why?
| | Hospitals | 4 | 2018 | 129 | 1.090 |
Why?
| | Infection Control | 5 | 2013 | 166 | 1.080 |
Why?
| | Algorithms | 10 | 2021 | 414 | 1.040 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 39 | 1.040 |
Why?
| | Sex Factors | 7 | 2019 | 524 | 1.030 |
Why?
| | Joint Prosthesis | 2 | 2015 | 73 | 1.020 |
Why?
| | Patient Selection | 8 | 2014 | 249 | 0.990 |
Why?
| | Anesthesia, Conduction | 2 | 2019 | 25 | 0.990 |
Why?
| | Anti-Infective Agents, Local | 2 | 2013 | 50 | 0.990 |
Why?
| | Osteolysis | 5 | 2015 | 137 | 0.950 |
Why?
| | Fracture Fixation, Internal | 5 | 2013 | 71 | 0.930 |
Why?
| | Morphine | 2 | 2019 | 78 | 0.930 |
Why?
| | Nail-Patella Syndrome | 1 | 2020 | 1 | 0.910 |
Why?
| | Refuse Disposal | 1 | 2020 | 3 | 0.900 |
Why?
| | Kaplan-Meier Estimate | 10 | 2019 | 226 | 0.900 |
Why?
| | Hospitalization | 2 | 2021 | 330 | 0.890 |
Why?
| | Corrosion | 7 | 2018 | 119 | 0.890 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 22 | 0.870 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2017 | 40 | 0.850 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 83 | 0.850 |
Why?
| | Preoperative Care | 9 | 2012 | 149 | 0.840 |
Why?
| | Hemoglobins | 3 | 2019 | 76 | 0.830 |
Why?
| | Databases, Factual | 9 | 2018 | 357 | 0.830 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 106 | 0.820 |
Why?
| | Pain Measurement | 11 | 2018 | 470 | 0.820 |
Why?
| | Hypoalbuminemia | 2 | 2015 | 3 | 0.820 |
Why?
| | Medial Collateral Ligament, Knee | 2 | 2016 | 6 | 0.820 |
Why?
| | Oxycodone | 1 | 2019 | 6 | 0.820 |
Why?
| | Frozen Sections | 4 | 2018 | 11 | 0.810 |
Why?
| | Fracture Fixation, Intramedullary | 2 | 2017 | 10 | 0.800 |
Why?
| | Anticoagulants | 6 | 2016 | 146 | 0.790 |
Why?
| | Patient Preference | 1 | 2019 | 34 | 0.790 |
Why?
| | Drug Prescriptions | 1 | 2019 | 35 | 0.790 |
Why?
| | ROC Curve | 8 | 2019 | 154 | 0.790 |
Why?
| | Carboxylic Ester Hydrolases | 4 | 2019 | 4 | 0.790 |
Why?
| | Quality of Life | 5 | 2020 | 604 | 0.790 |
Why?
| | Bone Transplantation | 2 | 2020 | 229 | 0.780 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2018 | 5 | 0.780 |
Why?
| | Patient Care Bundles | 1 | 2018 | 5 | 0.770 |
Why?
| | Risk Adjustment | 1 | 2018 | 14 | 0.770 |
Why?
| | Rehabilitation | 1 | 2018 | 15 | 0.760 |
Why?
| | Internship and Residency | 3 | 2019 | 182 | 0.760 |
Why?
| | Allografts | 2 | 2020 | 154 | 0.760 |
Why?
| | Hospitals, Private | 1 | 2017 | 2 | 0.760 |
Why?
| | Elective Surgical Procedures | 6 | 2019 | 53 | 0.750 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 78 | 0.750 |
Why?
| | Pain | 7 | 2019 | 315 | 0.750 |
Why?
| | Hospitals, Low-Volume | 1 | 2017 | 7 | 0.740 |
Why?
| | Hospitals, High-Volume | 1 | 2017 | 10 | 0.740 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 24 | 0.730 |
Why?
| | Antibiotic Prophylaxis | 4 | 2014 | 35 | 0.730 |
Why?
| | Equipment Failure Analysis | 6 | 2015 | 117 | 0.720 |
Why?
| | Patient Safety | 1 | 2018 | 53 | 0.710 |
Why?
| | Device Removal | 8 | 2014 | 97 | 0.710 |
Why?
| | Calcium Sulfate | 1 | 2017 | 29 | 0.710 |
Why?
| | Bone Plates | 3 | 2017 | 55 | 0.710 |
Why?
| | Acute Disease | 6 | 2017 | 272 | 0.700 |
Why?
| | Predictive Value of Tests | 13 | 2017 | 617 | 0.700 |
Why?
| | Recurrence | 9 | 2018 | 383 | 0.700 |
Why?
| | Nerve Block | 1 | 2017 | 57 | 0.700 |
Why?
| | Povidone-Iodine | 2 | 2019 | 8 | 0.700 |
Why?
| | Ceramics | 2 | 2015 | 22 | 0.690 |
Why?
| | Exercise Therapy | 1 | 2018 | 113 | 0.690 |
Why?
| | Practice Management | 1 | 2016 | 2 | 0.680 |
Why?
| | Diabetes Complications | 1 | 2017 | 66 | 0.680 |
Why?
| | Hospital Mortality | 1 | 2017 | 178 | 0.670 |
Why?
| | Chicago | 7 | 2018 | 916 | 0.670 |
Why?
| | Porosity | 8 | 2020 | 68 | 0.670 |
Why?
| | Commerce | 1 | 2016 | 11 | 0.660 |
Why?
| | Physicians | 1 | 2017 | 112 | 0.650 |
Why?
| | Attitude to Health | 2 | 2016 | 116 | 0.640 |
Why?
| | Biomechanical Phenomena | 8 | 2018 | 706 | 0.630 |
Why?
| | Logistic Models | 5 | 2019 | 478 | 0.620 |
Why?
| | Conflict of Interest | 1 | 2015 | 19 | 0.620 |
Why?
| | Bone Screws | 4 | 2017 | 175 | 0.620 |
Why?
| | Analgesics | 4 | 2020 | 101 | 0.600 |
Why?
| | Sutures | 2 | 2012 | 42 | 0.600 |
Why?
| | Nutritional Status | 1 | 2015 | 52 | 0.600 |
Why?
| | Knee | 4 | 2020 | 46 | 0.600 |
Why?
| | Microbiological Techniques | 2 | 2013 | 10 | 0.600 |
Why?
| | Drainage | 2 | 2018 | 54 | 0.590 |
Why?
| | Inflammation Mediators | 1 | 2014 | 88 | 0.560 |
Why?
| | Reagent Strips | 2 | 2016 | 3 | 0.560 |
Why?
| | Disinfection | 1 | 2013 | 13 | 0.560 |
Why?
| | Reconstructive Surgical Procedures | 3 | 2015 | 221 | 0.540 |
Why?
| | Health Expenditures | 3 | 2018 | 17 | 0.540 |
Why?
| | Patellar Ligament | 2 | 2015 | 47 | 0.540 |
Why?
| | Internal Fixators | 2 | 2010 | 53 | 0.530 |
Why?
| | Chlorhexidine | 1 | 2013 | 55 | 0.530 |
Why?
| | Postoperative Care | 4 | 2016 | 138 | 0.530 |
Why?
| | Disclosure | 3 | 2019 | 16 | 0.530 |
Why?
| | Awards and Prizes | 5 | 2017 | 19 | 0.500 |
Why?
| | Emergency Service, Hospital | 3 | 2021 | 165 | 0.500 |
Why?
| | Walking | 4 | 2018 | 231 | 0.490 |
Why?
| | Serologic Tests | 1 | 2011 | 13 | 0.480 |
Why?
| | Reproducibility of Results | 7 | 2019 | 857 | 0.480 |
Why?
| | Enterococcus | 3 | 2017 | 62 | 0.470 |
Why?
| | Blood Coagulation | 1 | 2011 | 28 | 0.460 |
Why?
| | Genetic Testing | 1 | 2011 | 75 | 0.450 |
Why?
| | Arthroscopy | 3 | 2016 | 732 | 0.450 |
Why?
| | Fractures, Ununited | 1 | 2010 | 20 | 0.450 |
Why?
| | Suture Techniques | 1 | 2011 | 138 | 0.450 |
Why?
| | Tantalum | 4 | 2017 | 34 | 0.440 |
Why?
| | Regression Analysis | 4 | 2019 | 318 | 0.430 |
Why?
| | Intra-Articular Fractures | 1 | 2010 | 14 | 0.430 |
Why?
| | Administration, Oral | 4 | 2020 | 164 | 0.430 |
Why?
| | Pelvic Bones | 1 | 2010 | 20 | 0.430 |
Why?
| | Perioperative Care | 1 | 2010 | 75 | 0.420 |
Why?
| | Risk | 3 | 2019 | 231 | 0.420 |
Why?
| | Prevalence | 6 | 2013 | 533 | 0.420 |
Why?
| | Bone Nails | 2 | 2007 | 16 | 0.420 |
Why?
| | Leg Length Inequality | 2 | 2016 | 12 | 0.410 |
Why?
| | Quality of Health Care | 4 | 2018 | 134 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2017 | 288 | 0.410 |
Why?
| | Anesthesia | 1 | 2009 | 27 | 0.400 |
Why?
| | Chromium Alloys | 4 | 2021 | 45 | 0.400 |
Why?
| | Achilles Tendon | 1 | 2008 | 23 | 0.400 |
Why?
| | Device Approval | 1 | 2008 | 17 | 0.400 |
Why?
| | Chi-Square Distribution | 5 | 2016 | 181 | 0.390 |
Why?
| | Titanium | 5 | 2016 | 201 | 0.390 |
Why?
| | Cementation | 6 | 2010 | 33 | 0.390 |
Why?
| | Reimbursement Mechanisms | 2 | 2012 | 13 | 0.390 |
Why?
| | Venous Thromboembolism | 3 | 2016 | 53 | 0.390 |
Why?
| | Ketorolac | 2 | 2020 | 16 | 0.390 |
Why?
| | Neutrophils | 5 | 2020 | 125 | 0.390 |
Why?
| | United States Food and Drug Administration | 1 | 2008 | 77 | 0.380 |
Why?
| | Area Under Curve | 4 | 2018 | 78 | 0.380 |
Why?
| | Age Factors | 7 | 2018 | 912 | 0.380 |
Why?
| | Enterocolitis, Pseudomembranous | 2 | 2018 | 16 | 0.380 |
Why?
| | Staphylococcus aureus | 2 | 2019 | 81 | 0.370 |
Why?
| | Preoperative Period | 2 | 2020 | 72 | 0.370 |
Why?
| | Ambulatory Care Facilities | 2 | 2018 | 39 | 0.350 |
Why?
| | Administration, Intravenous | 2 | 2017 | 35 | 0.340 |
Why?
| | Iliac Artery | 2 | 2009 | 8 | 0.340 |
Why?
| | Femoral Neck Fractures | 3 | 2018 | 12 | 0.340 |
Why?
| | Bone Malalignment | 2 | 2021 | 20 | 0.340 |
Why?
| | Double-Blind Method | 3 | 2017 | 541 | 0.330 |
Why?
| | Warfarin | 3 | 2016 | 61 | 0.320 |
Why?
| | Diagnostic Imaging | 2 | 2020 | 95 | 0.310 |
Why?
| | Joints | 2 | 2016 | 101 | 0.310 |
Why?
| | Severity of Illness Index | 6 | 2019 | 1220 | 0.310 |
Why?
| | Physician-Patient Relations | 2 | 2016 | 47 | 0.310 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2011 | 19 | 0.310 |
Why?
| | Prognosis | 4 | 2017 | 1025 | 0.310 |
Why?
| | Disease Management | 3 | 2015 | 149 | 0.310 |
Why?
| | Spine | 2 | 2018 | 115 | 0.300 |
Why?
| | Child, Preschool | 2 | 2020 | 785 | 0.300 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2016 | 63 | 0.290 |
Why?
| | Terminology as Topic | 2 | 2016 | 52 | 0.280 |
Why?
| | Wound Healing | 3 | 2018 | 171 | 0.280 |
Why?
| | Heparin | 2 | 2002 | 38 | 0.280 |
Why?
| | Patella | 4 | 2015 | 67 | 0.270 |
Why?
| | Clinical Competence | 3 | 2019 | 268 | 0.270 |
Why?
| | Fracture Fixation | 1 | 2003 | 26 | 0.270 |
Why?
| | Femur Head Necrosis | 3 | 2012 | 9 | 0.270 |
Why?
| | Consensus | 2 | 2021 | 90 | 0.260 |
Why?
| | Chronic Disease | 6 | 2020 | 530 | 0.260 |
Why?
| | Child | 2 | 2020 | 1505 | 0.260 |
Why?
| | Early Ambulation | 3 | 2019 | 20 | 0.260 |
Why?
| | Arthritis | 2 | 2020 | 110 | 0.260 |
Why?
| | Early Diagnosis | 2 | 2014 | 76 | 0.250 |
Why?
| | Fractures, Bone | 1 | 2003 | 60 | 0.250 |
Why?
| | Femoral Nerve | 2 | 2018 | 8 | 0.250 |
Why?
| | Specimen Handling | 2 | 2020 | 51 | 0.250 |
Why?
| | Cartilage, Articular | 3 | 2017 | 578 | 0.250 |
Why?
| | Bandages | 1 | 2002 | 10 | 0.250 |
Why?
| | Magnetic Resonance Imaging | 4 | 2021 | 1220 | 0.250 |
Why?
| | Equipment Design | 3 | 2011 | 198 | 0.240 |
Why?
| | Learning Curve | 1 | 2021 | 18 | 0.240 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2002 | 64 | 0.240 |
Why?
| | Muscle, Skeletal | 3 | 2018 | 368 | 0.240 |
Why?
| | Health Services Accessibility | 2 | 2021 | 106 | 0.240 |
Why?
| | Iliac Vein | 1 | 2001 | 5 | 0.230 |
Why?
| | Gentamicins | 2 | 2018 | 15 | 0.230 |
Why?
| | Tobramycin | 2 | 2018 | 11 | 0.230 |
Why?
| | Lumbosacral Plexus | 1 | 2001 | 6 | 0.230 |
Why?
| | Propensity Score | 2 | 2018 | 51 | 0.230 |
Why?
| | Tendinopathy | 1 | 2001 | 61 | 0.230 |
Why?
| | Fibrinolytic Agents | 1 | 2002 | 92 | 0.230 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2011 | 50 | 0.230 |
Why?
| | Diphosphonates | 1 | 2020 | 13 | 0.220 |
Why?
| | Acetaminophen | 1 | 2020 | 17 | 0.220 |
Why?
| | Cluster Analysis | 1 | 2020 | 56 | 0.220 |
Why?
| | Morbidity | 2 | 2017 | 71 | 0.220 |
Why?
| | Single-Blind Method | 1 | 2020 | 132 | 0.220 |
Why?
| | Synovial Membrane | 3 | 2013 | 79 | 0.220 |
Why?
| | Benzodiazepines | 1 | 2020 | 59 | 0.220 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 99 | 0.220 |
Why?
| | Bacitracin | 1 | 2019 | 1 | 0.220 |
Why?
| | Polymyxins | 1 | 2019 | 2 | 0.220 |
Why?
| | Perioperative Period | 2 | 2017 | 13 | 0.210 |
Why?
| | Antidepressive Agents | 1 | 2020 | 107 | 0.210 |
Why?
| | Escherichia coli | 1 | 2019 | 67 | 0.210 |
Why?
| | Gallium | 2 | 2016 | 4 | 0.210 |
Why?
| | Attitude | 1 | 2019 | 30 | 0.210 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1999 | 3 | 0.210 |
Why?
| | Embolism, Paradoxical | 1 | 1999 | 8 | 0.200 |
Why?
| | Tendons | 3 | 2006 | 205 | 0.200 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 35 | 0.200 |
Why?
| | Fracture Healing | 3 | 2010 | 41 | 0.200 |
Why?
| | Life Expectancy | 1 | 2018 | 19 | 0.200 |
Why?
| | Staphylococcal Infections | 3 | 2017 | 165 | 0.200 |
Why?
| | Cost-Benefit Analysis | 2 | 2016 | 144 | 0.200 |
Why?
| | Heart Arrest | 1 | 2019 | 52 | 0.200 |
Why?
| | Illinois | 3 | 2018 | 265 | 0.200 |
Why?
| | Surgical Wound Dehiscence | 1 | 2018 | 12 | 0.190 |
Why?
| | Personal Satisfaction | 1 | 2018 | 50 | 0.190 |
Why?
| | Costs and Cost Analysis | 1 | 2018 | 39 | 0.190 |
Why?
| | Injury Severity Score | 1 | 2017 | 22 | 0.190 |
Why?
| | Hand | 1 | 2018 | 47 | 0.190 |
Why?
| | False Positive Reactions | 1 | 2018 | 40 | 0.190 |
Why?
| | Longitudinal Studies | 2 | 2021 | 1388 | 0.190 |
Why?
| | Delivery of Health Care | 2 | 2020 | 110 | 0.190 |
Why?
| | Anti-Inflammatory Agents | 2 | 2016 | 108 | 0.190 |
Why?
| | Thigh | 1 | 2017 | 36 | 0.190 |
Why?
| | Hospital Charges | 1 | 2017 | 22 | 0.180 |
Why?
| | Myocardial Infarction | 1 | 2019 | 188 | 0.180 |
Why?
| | Disease-Free Survival | 1 | 2018 | 245 | 0.180 |
Why?
| | Counseling | 1 | 2017 | 64 | 0.180 |
Why?
| | Reading | 1 | 2017 | 36 | 0.180 |
Why?
| | Acute Kidney Injury | 1 | 2018 | 58 | 0.180 |
Why?
| | Comprehension | 1 | 2017 | 31 | 0.180 |
Why?
| | Health Policy | 1 | 2017 | 49 | 0.180 |
Why?
| | Leukocytes | 1 | 2017 | 49 | 0.180 |
Why?
| | Disability Evaluation | 3 | 2014 | 327 | 0.180 |
Why?
| | Activities of Daily Living | 3 | 2020 | 470 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 357 | 0.180 |
Why?
| | Anemia | 1 | 2018 | 90 | 0.180 |
Why?
| | Decision Trees | 2 | 2011 | 20 | 0.170 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 379 | 0.170 |
Why?
| | Vasculitis | 1 | 2016 | 35 | 0.170 |
Why?
| | Health Status | 1 | 2018 | 250 | 0.170 |
Why?
| | Prosthesis Fitting | 3 | 2012 | 23 | 0.170 |
Why?
| | Pelvis | 1 | 2016 | 26 | 0.170 |
Why?
| | Injections, Intravenous | 1 | 2016 | 61 | 0.170 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 466 | 0.170 |
Why?
| | Survival Rate | 1 | 2017 | 464 | 0.170 |
Why?
| | Internet | 1 | 2017 | 96 | 0.170 |
Why?
| | Replantation | 1 | 2016 | 7 | 0.170 |
Why?
| | Ethics, Medical | 1 | 2016 | 17 | 0.170 |
Why?
| | Nanostructures | 1 | 2016 | 13 | 0.170 |
Why?
| | Silver | 1 | 2015 | 4 | 0.170 |
Why?
| | Cost Savings | 1 | 2016 | 39 | 0.160 |
Why?
| | Acinetobacter baumannii | 1 | 2015 | 5 | 0.160 |
Why?
| | Acinetobacter Infections | 1 | 2015 | 6 | 0.160 |
Why?
| | Arthritis, Rheumatoid | 3 | 2019 | 374 | 0.160 |
Why?
| | Geriatric Assessment | 1 | 2017 | 229 | 0.160 |
Why?
| | Emergency Medical Services | 1 | 2016 | 39 | 0.160 |
Why?
| | Cartilage Diseases | 1 | 2017 | 75 | 0.160 |
Why?
| | Dexamethasone | 1 | 2016 | 52 | 0.160 |
Why?
| | Hematocrit | 1 | 2015 | 15 | 0.160 |
Why?
| | Anterior Cruciate Ligament | 1 | 2018 | 254 | 0.160 |
Why?
| | Bupivacaine | 1 | 2016 | 55 | 0.160 |
Why?
| | Private Practice | 1 | 1995 | 6 | 0.160 |
Why?
| | Aspirin | 2 | 2010 | 86 | 0.160 |
Why?
| | Industry | 1 | 2015 | 11 | 0.160 |
Why?
| | Suction | 3 | 2011 | 45 | 0.160 |
Why?
| | Surgical Flaps | 1 | 2015 | 54 | 0.160 |
Why?
| | Insurance, Health | 1 | 1995 | 27 | 0.160 |
Why?
| | Osteogenesis | 1 | 2016 | 93 | 0.160 |
Why?
| | Anesthetics, Local | 1 | 2016 | 85 | 0.160 |
Why?
| | Knee Injuries | 2 | 2015 | 219 | 0.150 |
Why?
| | Nutrition Assessment | 1 | 2015 | 53 | 0.150 |
Why?
| | Patients | 1 | 2015 | 24 | 0.150 |
Why?
| | Equipment Failure | 2 | 2013 | 53 | 0.150 |
Why?
| | Arthralgia | 1 | 2016 | 115 | 0.150 |
Why?
| | False Negative Reactions | 1 | 2014 | 16 | 0.150 |
Why?
| | Perception | 1 | 2015 | 85 | 0.150 |
Why?
| | Seroma | 1 | 2014 | 4 | 0.150 |
Why?
| | Sexual Behavior | 1 | 2014 | 64 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 3 | 2012 | 869 | 0.140 |
Why?
| | Obesity | 1 | 2017 | 316 | 0.140 |
Why?
| | Research Design | 1 | 2016 | 227 | 0.140 |
Why?
| | Posterior Cruciate Ligament | 2 | 2011 | 23 | 0.140 |
Why?
| | Meta-Analysis as Topic | 1 | 2013 | 43 | 0.140 |
Why?
| | Monitoring, Intraoperative | 1 | 2014 | 41 | 0.140 |
Why?
| | Orthopedic Fixation Devices | 1 | 2013 | 24 | 0.140 |
Why?
| | Osteoarthritis | 2 | 2013 | 354 | 0.140 |
Why?
| | Aminoglycosides | 1 | 2013 | 12 | 0.140 |
Why?
| | Return to Work | 1 | 2014 | 46 | 0.140 |
Why?
| | Physical Examination | 2 | 2011 | 111 | 0.140 |
Why?
| | Treatment Failure | 4 | 2016 | 186 | 0.140 |
Why?
| | Sex Distribution | 1 | 2013 | 90 | 0.130 |
Why?
| | Age Distribution | 1 | 2013 | 115 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2015 | 223 | 0.130 |
Why?
| | Bone Remodeling | 1 | 2013 | 43 | 0.130 |
Why?
| | Point-of-Care Systems | 1 | 2013 | 29 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2013 | 39 | 0.130 |
Why?
| | Platelet-Rich Plasma | 1 | 2013 | 64 | 0.130 |
Why?
| | Clinical Enzyme Tests | 1 | 2012 | 2 | 0.130 |
Why?
| | Femoracetabular Impingement | 2 | 2013 | 137 | 0.130 |
Why?
| | Spinal Fusion | 1 | 1999 | 425 | 0.130 |
Why?
| | Triage | 1 | 2012 | 29 | 0.130 |
Why?
| | Blood Chemical Analysis | 1 | 2012 | 17 | 0.130 |
Why?
| | Bacteremia | 1 | 2013 | 122 | 0.130 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2011 | 15 | 0.130 |
Why?
| | Substance P | 1 | 2011 | 19 | 0.120 |
Why?
| | Transplantation, Homologous | 3 | 2008 | 283 | 0.120 |
Why?
| | Norepinephrine | 1 | 2011 | 33 | 0.120 |
Why?
| | Drug Administration Schedule | 3 | 2020 | 265 | 0.120 |
Why?
| | Biocompatible Materials | 2 | 2017 | 112 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2011 | 35 | 0.120 |
Why?
| | Causality | 1 | 2011 | 58 | 0.120 |
Why?
| | Work Capacity Evaluation | 1 | 2011 | 8 | 0.120 |
Why?
| | Wound Closure Techniques | 1 | 2011 | 9 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2011 | 54 | 0.120 |
Why?
| | Silicones | 1 | 2011 | 14 | 0.120 |
Why?
| | Philadelphia | 1 | 2011 | 6 | 0.120 |
Why?
| | Pedigree | 1 | 2011 | 86 | 0.120 |
Why?
| | Infant | 1 | 2013 | 652 | 0.120 |
Why?
| | Case-Control Studies | 1 | 2013 | 684 | 0.120 |
Why?
| | Biopsy, Fine-Needle | 1 | 2010 | 53 | 0.110 |
Why?
| | Data Collection | 3 | 2018 | 118 | 0.110 |
Why?
| | Drug Interactions | 1 | 2010 | 71 | 0.110 |
Why?
| | International Normalized Ratio | 1 | 2010 | 32 | 0.110 |
Why?
| | Proteins | 1 | 2010 | 86 | 0.110 |
Why?
| | Candida | 1 | 2009 | 16 | 0.110 |
Why?
| | Mycoses | 1 | 2009 | 21 | 0.110 |
Why?
| | Phenotype | 1 | 2011 | 360 | 0.100 |
Why?
| | Foreign-Body Migration | 1 | 2009 | 20 | 0.100 |
Why?
| | Pilot Projects | 1 | 2011 | 425 | 0.100 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2019 | 13 | 0.100 |
Why?
| | Animals | 7 | 2016 | 5125 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 469 | 0.090 |
Why?
| | Probability | 2 | 2004 | 107 | 0.090 |
Why?
| | Canada | 2 | 2020 | 55 | 0.090 |
Why?
| | Guided Tissue Regeneration | 1 | 2006 | 11 | 0.090 |
Why?
| | New York | 2 | 2003 | 13 | 0.080 |
Why?
| | Critical Pathways | 1 | 2006 | 23 | 0.080 |
Why?
| | Vena Cava Filters | 2 | 2011 | 10 | 0.080 |
Why?
| | Tendon Injuries | 2 | 2005 | 187 | 0.080 |
Why?
| | Surface Properties | 2 | 2016 | 137 | 0.080 |
Why?
| | Interviews as Topic | 3 | 2015 | 138 | 0.080 |
Why?
| | Gait | 2 | 2016 | 378 | 0.070 |
Why?
| | Sampling Studies | 1 | 2003 | 31 | 0.070 |
Why?
| | Polyethylenes | 1 | 2004 | 41 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2014 | 351 | 0.070 |
Why?
| | Polymethyl Methacrylate | 1 | 2002 | 16 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 467 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 41 | 0.060 |
Why?
| | Dextrans | 1 | 2002 | 6 | 0.060 |
Why?
| | Physician Executives | 1 | 2002 | 5 | 0.060 |
Why?
| | School Admission Criteria | 1 | 2002 | 11 | 0.060 |
Why?
| | Groin | 1 | 2001 | 6 | 0.060 |
Why?
| | Hypersensitivity | 1 | 2002 | 52 | 0.060 |
Why?
| | Personnel Selection | 1 | 2002 | 25 | 0.060 |
Why?
| | Students, Medical | 1 | 2002 | 44 | 0.060 |
Why?
| | Materials Testing | 2 | 2016 | 139 | 0.060 |
Why?
| | Subacute Care | 1 | 2021 | 2 | 0.060 |
Why?
| | Obturator Nerve | 1 | 2001 | 1 | 0.060 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 16 | 0.060 |
Why?
| | Ontario | 1 | 2021 | 17 | 0.060 |
Why?
| | Catastrophization | 1 | 2021 | 15 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2002 | 82 | 0.060 |
Why?
| | Gene Expression | 2 | 2013 | 270 | 0.060 |
Why?
| | Sciatic Nerve | 1 | 2001 | 32 | 0.060 |
Why?
| | Patellofemoral Joint | 2 | 2012 | 31 | 0.060 |
Why?
| | Anesthesia, Epidural | 2 | 2011 | 29 | 0.060 |
Why?
| | Demography | 1 | 2020 | 80 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 162 | 0.060 |
Why?
| | Australia | 1 | 2020 | 43 | 0.060 |
Why?
| | Rib Fractures | 1 | 2000 | 2 | 0.060 |
Why?
| | Current Procedural Terminology | 1 | 2019 | 13 | 0.050 |
Why?
| | Europe | 1 | 2020 | 83 | 0.050 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 15 | 0.050 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 177 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2000 | 106 | 0.050 |
Why?
| | Solutions | 1 | 2019 | 19 | 0.050 |
Why?
| | Drug Administration Routes | 1 | 2019 | 10 | 0.050 |
Why?
| | Gentian Violet | 1 | 1999 | 4 | 0.050 |
Why?
| | Phenazines | 1 | 1999 | 6 | 0.050 |
Why?
| | Cartilage | 1 | 2021 | 166 | 0.050 |
Why?
| | Staining and Labeling | 1 | 1999 | 27 | 0.050 |
Why?
| | Pain Perception | 1 | 2019 | 7 | 0.050 |
Why?
| | Hemorrhage | 1 | 2000 | 87 | 0.050 |
Why?
| | Pregnancy Complications | 1 | 2000 | 56 | 0.050 |
Why?
| | Glycoproteins | 1 | 1999 | 66 | 0.050 |
Why?
| | Fee-for-Service Plans | 1 | 2018 | 5 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2012 | 915 | 0.050 |
Why?
| | Models, Economic | 1 | 2018 | 10 | 0.050 |
Why?
| | Heart Septal Defects, Atrial | 1 | 1999 | 25 | 0.050 |
Why?
| | Chondrosarcoma | 1 | 1998 | 36 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 1998 | 48 | 0.050 |
Why?
| | Rupture | 2 | 2012 | 114 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 481 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 16 | 0.050 |
Why?
| | Nitric Oxide | 1 | 1998 | 108 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 1999 | 177 | 0.050 |
Why?
| | Operating Rooms | 1 | 2018 | 17 | 0.050 |
Why?
| | Medicaid | 1 | 2018 | 41 | 0.050 |
Why?
| | Electromyography | 1 | 2018 | 89 | 0.050 |
Why?
| | Absorption, Physiological | 1 | 2017 | 2 | 0.050 |
Why?
| | Creatinine | 1 | 2018 | 56 | 0.050 |
Why?
| | Amputation | 1 | 2018 | 20 | 0.050 |
Why?
| | Pregnancy | 2 | 2014 | 443 | 0.050 |
Why?
| | Clostridium difficile | 1 | 2017 | 19 | 0.050 |
Why?
| | Colitis | 1 | 2017 | 33 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 1998 | 114 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2017 | 62 | 0.040 |
Why?
| | Self Concept | 1 | 2016 | 52 | 0.040 |
Why?
| | Smoking | 1 | 2018 | 195 | 0.040 |
Why?
| | Societies | 1 | 2016 | 7 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 233 | 0.040 |
Why?
| | Injections | 1 | 2016 | 59 | 0.040 |
Why?
| | Exploratory Behavior | 1 | 2016 | 23 | 0.040 |
Why?
| | Drug Resistance, Multiple | 1 | 2015 | 12 | 0.040 |
Why?
| | Bacterial Adhesion | 1 | 2015 | 7 | 0.040 |
Why?
| | Midwestern United States | 1 | 2016 | 68 | 0.040 |
Why?
| | Noise | 1 | 2016 | 31 | 0.040 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2016 | 83 | 0.040 |
Why?
| | Biofilms | 1 | 2015 | 22 | 0.040 |
Why?
| | Kidney | 1 | 2017 | 205 | 0.040 |
Why?
| | Medical Assistance | 1 | 1995 | 2 | 0.040 |
Why?
| | Tissue Engineering | 1 | 2016 | 49 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 264 | 0.040 |
Why?
| | Medically Uninsured | 1 | 1995 | 11 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2016 | 106 | 0.040 |
Why?
| | Inflammation | 1 | 2018 | 338 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 54 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 96 | 0.040 |
Why?
| | Fetal Blood | 1 | 2014 | 18 | 0.040 |
Why?
| | Rabbits | 1 | 2016 | 325 | 0.040 |
Why?
| | Placenta | 1 | 2014 | 14 | 0.040 |
Why?
| | Nickel | 1 | 2014 | 28 | 0.040 |
Why?
| | Iatrogenic Disease | 1 | 2015 | 26 | 0.040 |
Why?
| | Cell Line | 1 | 2015 | 351 | 0.040 |
Why?
| | Global Health | 1 | 2015 | 57 | 0.040 |
Why?
| | Health Surveys | 1 | 2014 | 100 | 0.040 |
Why?
| | Hematologic Tests | 1 | 2014 | 6 | 0.040 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2013 | 7 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2013 | 39 | 0.040 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2013 | 36 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2014 | 27 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2013 | 57 | 0.030 |
Why?
| | Social Class | 1 | 2014 | 72 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 149 | 0.030 |
Why?
| | Collagen | 1 | 2013 | 111 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 206 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2013 | 116 | 0.030 |
Why?
| | Observer Variation | 1 | 2013 | 140 | 0.030 |
Why?
| | Osteonecrosis | 1 | 2013 | 18 | 0.030 |
Why?
| | Hyaluronic Acid | 1 | 2013 | 106 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2013 | 369 | 0.030 |
Why?
| | Aggrecans | 1 | 2013 | 197 | 0.030 |
Why?
| | California | 1 | 2012 | 33 | 0.030 |
Why?
| | Anthropometry | 1 | 2012 | 56 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 227 | 0.030 |
Why?
| | Motor Activity | 1 | 2016 | 387 | 0.030 |
Why?
| | Disease Progression | 2 | 2006 | 843 | 0.030 |
Why?
| | Fees and Charges | 1 | 2012 | 8 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2016 | 813 | 0.030 |
Why?
| | Intermittent Pneumatic Compression Devices | 1 | 2011 | 9 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2014 | 741 | 0.030 |
Why?
| | Pennsylvania | 1 | 2011 | 15 | 0.030 |
Why?
| | Staphylococcus | 1 | 2011 | 11 | 0.030 |
Why?
| | Spinal Puncture | 1 | 2011 | 23 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2011 | 29 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2011 | 35 | 0.030 |
Why?
| | Hemophilia A | 1 | 2011 | 39 | 0.030 |
Why?
| | Workload | 1 | 2011 | 39 | 0.030 |
Why?
| | Population Surveillance | 1 | 2012 | 125 | 0.030 |
Why?
| | Ultrasonography | 1 | 2012 | 198 | 0.030 |
Why?
| | Polymethacrylic Acids | 1 | 2010 | 5 | 0.030 |
Why?
| | Educational Status | 1 | 2012 | 271 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2010 | 70 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2009 | 37 | 0.030 |
Why?
| | Health Status Indicators | 1 | 2010 | 82 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 180 | 0.030 |
Why?
| | Anterior Cruciate Ligament Reconstruction | 1 | 2012 | 192 | 0.030 |
Why?
| | Vascular Surgical Procedures | 1 | 2009 | 55 | 0.020 |
Why?
| | RNA, Messenger | 2 | 1999 | 357 | 0.020 |
Why?
| | Connective Tissue | 1 | 2007 | 27 | 0.020 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2008 | 101 | 0.020 |
Why?
| | Supine Position | 1 | 2006 | 18 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2006 | 74 | 0.020 |
Why?
| | Research | 1 | 2006 | 62 | 0.020 |
Why?
| | Sleep | 1 | 2009 | 326 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2006 | 273 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 382 | 0.020 |
Why?
| | Weight-Bearing | 1 | 2004 | 193 | 0.020 |
Why?
| | Survival Analysis | 1 | 2004 | 390 | 0.020 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 25 | 0.020 |
Why?
| | Educational Measurement | 1 | 2002 | 65 | 0.020 |
Why?
| | Pregnancy Trimester, Third | 1 | 2000 | 6 | 0.010 |
Why?
| | Abdominal Pain | 1 | 2000 | 10 | 0.010 |
Why?
| | Cough | 1 | 2000 | 12 | 0.010 |
Why?
| | Cartilage Oligomeric Matrix Protein | 1 | 1999 | 1 | 0.010 |
Why?
| | Immunologic Techniques | 1 | 1999 | 6 | 0.010 |
Why?
| | Matrilin Proteins | 1 | 1999 | 3 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1999 | 50 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 61 | 0.010 |
Why?
| | Guanidines | 1 | 1998 | 3 | 0.010 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 1998 | 17 | 0.010 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 1998 | 70 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1998 | 138 | 0.010 |
Why?
| | Up-Regulation | 1 | 1998 | 214 | 0.010 |
Why?
| | Rats | 1 | 1998 | 941 | 0.010 |
Why?
|
|
Della Valle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|